Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavrilimumab long-term safety in rheumatoid arthritis (Earth Explorer X)
NCT01712399Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Jan 2013
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 2, open-label, single-arm trial of mavrilimumab in rheumatoid arthritis (RA), sponsored by MedImmune. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events at 156 weeks, Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events at 156 weeks and 8 more. Started Jan 2013; status: terminated.
02
Drugs
mavrilimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01712399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712399.